[{"id":"ff30d699-6a53-417a-9123-6d01ce11b0e9","acronym":"LITESPARK-005","url":"https://clinicaltrials.gov/study/NCT04195750","created_at":"2021-01-18T20:26:57.399Z","updated_at":"2025-02-25T14:07:37.008Z","phase":"Phase 3","brief_title":"A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)","source_id_and_acronym":"NCT04195750 - LITESPARK-005","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus • Welireg (belzutifan)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 755","initiation":"Initiation: 02/27/2020","start_date":" 02/27/2020","primary_txt":" Primary completion: 04/15/2024","primary_completion_date":" 04/15/2024","study_txt":" Completion: 09/17/2026","study_completion_date":" 09/17/2026","last_update_posted":"2025-02-17"},{"id":"231092fb-00ef-4553-bd1a-e401bd09459d","acronym":"LITESPARK-016","url":"https://clinicaltrials.gov/study/NCT04976634","created_at":"2021-07-26T17:53:23.648Z","updated_at":"2025-02-25T15:19:12.763Z","phase":"Phase 2","brief_title":"Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)","source_id_and_acronym":"NCT04976634 - LITESPARK-016","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" MSI","pipe":"","alterations":" ","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Lenvima (lenvatinib) • Welireg (belzutifan)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 730","initiation":"Initiation: 08/18/2021","start_date":" 08/18/2021","primary_txt":" Primary completion: 03/22/2027","primary_completion_date":" 03/22/2027","study_txt":" Completion: 03/22/2027","study_completion_date":" 03/22/2027","last_update_posted":"2025-02-12"},{"id":"67176e4e-5f06-435a-a426-189730ad7d5a","acronym":"LITESPARK-015","url":"https://clinicaltrials.gov/study/NCT04924075","created_at":"2021-07-05T17:36:40.354Z","updated_at":"2025-02-25T15:26:55.556Z","phase":"Phase 2","brief_title":"Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)","source_id_and_acronym":"NCT04924075 - LITESPARK-015","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" KIT • PDGFRA • VHL • EPAS1","pipe":" | ","alterations":" PDGFRA mutation","tags":["KIT • PDGFRA • VHL • EPAS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PDGFRA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Welireg (belzutifan)"],"overall_status":"Recruiting","enrollment":" Enrollment 322","initiation":"Initiation: 08/12/2021","start_date":" 08/12/2021","primary_txt":" Primary completion: 06/04/2029","primary_completion_date":" 06/04/2029","study_txt":" Completion: 06/04/2029","study_completion_date":" 06/04/2029","last_update_posted":"2025-02-11"},{"id":"be1fb378-e645-4d44-9ccb-5000075d9948","acronym":"LITESPARK-013","url":"https://clinicaltrials.gov/study/NCT04489771","created_at":"2021-01-18T21:34:23.608Z","updated_at":"2025-02-25T15:26:26.915Z","phase":"Phase 2","brief_title":"A Study of Belzutifan (MK-6482) in Participants With Advanced Renal Cell Carcinoma (MK-6482-013)","source_id_and_acronym":"NCT04489771 - LITESPARK-013","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" CTLA4","pipe":"","alterations":" ","tags":["CTLA4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Welireg (belzutifan)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 154","initiation":"Initiation: 09/13/2020","start_date":" 09/13/2020","primary_txt":" Primary completion: 02/10/2023","primary_completion_date":" 02/10/2023","study_txt":" Completion: 10/04/2026","study_completion_date":" 10/04/2026","last_update_posted":"2025-02-11"},{"id":"28905f7c-1ba3-4c54-b0ee-8bfef8ba9fd0","acronym":"CDFF332A12101","url":"https://clinicaltrials.gov/study/NCT04895748","created_at":"2021-05-20T11:54:08.339Z","updated_at":"2024-07-02T16:35:03.755Z","phase":"Phase 1","brief_title":"DFF332 as a Single Agent and in Combination With Everolimus \u0026 Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer \u0026 Other Malignancies","source_id_and_acronym":"NCT04895748 - CDFF332A12101","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" VHL • SDHB • EPAS1 • SDHC • SDHD • SDHA • SDHAF2","pipe":" | ","alterations":" VHL mutation • SDHB mutation","tags":["VHL • SDHB • EPAS1 • SDHC • SDHD • SDHA • SDHAF2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e VHL mutation • SDHB mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus • spartalizumab (PDR001) • DFF332 • taminadenant (NIR178)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 11/30/2021","start_date":" 11/30/2021","primary_txt":" Primary completion: 02/28/2025","primary_completion_date":" 02/28/2025","study_txt":" Completion: 02/28/2025","study_completion_date":" 02/28/2025","last_update_posted":"2024-05-14"},{"id":"57151d05-381a-48a1-843f-46d3073ad3fb","acronym":"","url":"https://clinicaltrials.gov/study/NCT05119335","created_at":"2021-11-15T13:53:41.126Z","updated_at":"2024-07-02T16:35:27.466Z","phase":"Phase 1/2","brief_title":"A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma","source_id_and_acronym":"NCT05119335","lead_sponsor":"NiKang Therapeutics, Inc.","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imdatifan (NKT2152)"],"overall_status":"Recruiting","enrollment":" Enrollment 128","initiation":"Initiation: 10/26/2021","start_date":" 10/26/2021","primary_txt":" Primary completion: 09/01/2024","primary_completion_date":" 09/01/2024","study_txt":" Completion: 09/01/2026","study_completion_date":" 09/01/2026","last_update_posted":"2023-11-30"},{"id":"59cd4907-7414-4a7a-8621-ea3eec8b43bb","acronym":"","url":"https://clinicaltrials.gov/study/NCT00736645","created_at":"2023-10-02T22:10:46.115Z","updated_at":"2024-07-02T16:35:35.090Z","phase":"Phase 2","brief_title":"Selenomethionine and Finasteride Before Surgery or Radiation Therapy in Treating Patients With Stage I or Stage II Prostate Cancer","source_id_and_acronym":"NCT00736645","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" CASP3","pipe":"","alterations":" ","tags":["CASP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e finasteride • selenomethionine (SLM)"],"overall_status":"Completed","enrollment":" Enrollment 55","initiation":"Initiation: 08/01/2008","start_date":" 08/01/2008","primary_txt":" Primary completion: 12/01/2012","primary_completion_date":" 12/01/2012","study_txt":" Completion: 12/01/2012","study_completion_date":" 12/01/2012","last_update_posted":"2023-10-02"},{"id":"160a70b8-6f49-4ee1-ba97-f6f7d4157dc6","acronym":"","url":"https://clinicaltrials.gov/study/NCT03216499","created_at":"2021-01-18T15:52:16.143Z","updated_at":"2025-02-25T16:06:33.407Z","phase":"Phase 2","brief_title":"HIF-2 Alpha Inhibitor PT2385 in Treating Patients With Recurrent Glioblastoma","source_id_and_acronym":"NCT03216499","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" MGMT","pipe":"","alterations":" ","tags":["MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MK-3795"],"overall_status":"Completed","enrollment":" Enrollment 24","initiation":"Initiation: 09/14/2017","start_date":" 09/14/2017","primary_txt":" Primary completion: 08/31/2019","primary_completion_date":" 08/31/2019","study_txt":" Completion: 06/05/2020","study_completion_date":" 06/05/2020","last_update_posted":"2022-05-09"}]